WARNINGS Patients treated with parenteral aminoglycosides should be under close clinical observation because of the potential ototoxicity and nephrotoxicity associated with their use. Safety for treatment periods which are longer than 14 days has not been established. Neurotoxicity, manifested as vestibular and permanent bilateral auditory ototoxicity, can occur in patients with preexisting renal damage and in patients with normal renal function treated at higher doses and/or for periods longer than those recommended.
The risk of aminoglycoside-induced ototoxicity is greater in patients with renal damage. High frequency deafness usually occurs first and can be detected only by audiometric testing. Vertigo may occur and may be evidence of vestibular injury. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching and convulsions.
The risk of hearing loss due to aminoglycosides increases with the degree of exposure to either high peak or high trough serum concentrations. Patients developing cochlear damage may not have symptoms during therapy to warn them of developing eighth-nerve toxicity, and total or partial irreversible bilateral deafness may occur after the drug has been discontinued.
Aminoglycoside-induced ototoxicity is usually irreversible. Aminoglycosides are potentially nephrotoxic. The risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive high doses or prolonged therapy. Neuromuscular blockade and respiratory paralysis have been reported following parenteral injection, topical instillation (as in orthopedic and abdominal irrigation or in local treatment of empyema), and following oral use of aminoglycosides.
The possibility of these phenomena should be considered if aminoglycosides are administered by any route, especially in patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate-anticoagulated blood. If blockage occurs, calcium salts may reverse these phenomena, but mechanical respiratory assistance may be necessary.
Renal and eighth-nerve function should be closely monitored especially in patients with known or suspected renal impairment at the onset of therapy and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Serum concentrations of amikacin should be monitored when feasible to assure adequate levels and to avoid potentially toxic levels and prolonged peak concentrations above 35 micrograms per mL.
Urine should be examined for decreased specific gravity, increased excretion of proteins, and the presence of cells or casts. Blood urea nitrogen, serum creatinine, or creatinine clearance should be measured periodically. Serial audiograms should be obtained where feasible in patients old enough to be tested, particularly high risk patients.
Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears, and hearing loss) or nephrotoxicity requires discontinuation of the drug or dosage adjustment. Concurrent and/or sequential systemic, oral or topical use of other neurotoxic or nephrotoxic products, particularly bacitracin, cisplatin, amphotericin B, cephaloridine, paromomycin, viomycin, polymyxin B, colistin, vancomycin, or other aminoglycosides should be avoided.
Other factors that may increase risk of toxicity are advanced age and dehydration. The concurrent use of amikacin with potent diuretics (ethacrynic acid, or furosemide) should be avoided since diuretics by themselves may cause ototoxicity. In addition, when administered intravenously, diuretics may enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.
Use: Labeled indications
- INDICATIONS AND USAGE Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli…
Full indications and usage US FDA label
INDICATIONS AND USAGE Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter (Mima-Herellea) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery).
Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity.
Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri, Providencia stuartii, Serratia marcescens, and Pseudomonas aeruginosa.
The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections.
In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications
- Hypersensitivity to amikacin (history of serious reaction to other aminoglycosides may also contraindicate)
Contraindications (US label) US FDA label
CONTRAINDICATIONS A history of hypersensitivity to amikacin is a contraindication for its use. A history of hypersensitivity or serious toxic reactions to aminoglycosides may contraindicate the use of any other aminoglycoside because of the known cross-sensitivities of patients to drugs in this class.
Dosing: Adult
- Serious gram-negative infections (normal kidney function): 15 mg/kg/day IM or IV in 2 or 3 equal doses; maximum 1.5 g/day; usually 7 to 10 days
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION The patient's pretreatment body weight should be obtained for calculation of correct dosage. Amikacin Sulfate Injection, USP may be given intramuscularly or intravenously. The status of renal function should be estimated by measurement of the serum creatinine concentration or calculation of the endogenous creatinine clearance rate.
The blood urea nitrogen (BUN) is much less reliable for this purpose. Reassessment of renal function should be made periodically during therapy. Whenever possible, amikacin concentrations in serum should be measured to assure adequate but not excessive levels. It is desirable to measure both peak and trough serum concentrations intermittently during therapy.
Peak concentrations (30 to 90 minutes after injection) above 35 micrograms per mL and trough concentrations (just prior to the next dose) above 10 micrograms per mL should be avoided. Dosage should be adjusted as indicated. Intramuscular Administration for Patients with Normal Renal Function The recommended dosage for adults, children and older infants (see WARNINGS box) with normal renal function is 15 mg/kg/day divided into 2 or 3 equal doses administered at equally-divided intervals, i.e., 7.5 mg/kg q12h or 5 mg/kg q8h.
Treatment of patients in the heavier weight classes should not exceed 1.5 gram/day. When amikacin is indicated in newborns (see WARNINGS box), it is recommended that a loading dose of 10 mg/kg be administered initially to be followed with 7.5 mg/kg every 12 hours. The usual duration of treatment is 7 to 10 days. It is desirable to limit the duration of treatment to short term whenever feasible.
The total daily dose by all routes of administration should not exceed 15 mg/kg/day. In difficult and complicated infections where treatment beyond 10 days is considered, the use of amikacin should be reevaluated. If continued, amikacin serum levels, and renal, auditory, and vestibular functions should be monitored. At the recommended dosage level, uncomplicated infections due to amikacin-sensitive organisms should respond in 24 to 48 hours.
If definite clinical response does not occur within 3 to 5 days, therapy should be stopped and the antibiotic susceptibility pattern of the invading organism should be rechecked. Failure of the infection to respond may be due to resistance of the organism or to the presence of septic foci requiring surgical drainage. When amikacin is indicated in uncomplicated urinary tract infections, a dose of 250 mg twice daily may be used.
DOSAGE GUIDELINES ADULTS AND CHILDREN WITH NORMAL RENAL FUNCTION Patient Weight Dosage lbs kg 7.5 mg/kg 5 mg/kg q12h OR q8h 99 45 337.5 mg 225 mg 110 50 375 mg 250 mg 121 55 412.5 mg 275 mg 132 60 450 mg 300 mg 143 65 487.5 mg 325 mg 154 70 525 mg 350 mg 165 75 562.5 mg 375 mg 176 80 600 mg 400 mg 187 85 637.5 mg 425 mg 198 90 675 mg 450 mg 209 95 712.5 mg 475 mg 220 100 750 mg 500 mg Intramuscular Administration for Patients with Impaired Renal Function Whenever possible, serum amikacin concentrations should be monitored by appropriate assay procedures. Doses may be adjusted in patients with impaired renal function either by administering normal doses at prolonged intervals or by administrating reduced doses at a fixed interval.
Both methods are based on the patient's creatinine clearance or serum creatinine values since these have been found to correlate with aminoglycoside half-lives in patients with diminished renal function. These dosage schedules must be used in conjunction with careful clinical and laboratory observations of the patient and should be modified as necessary.
Neither method should be used when dialysis is being performed. Normal Dosage at Prolonged Intervals If the creatinine clearance rate is not available and the patient's condition is stable, a dosage interval in hours for the normal dose can be calculated by multiplying the patient's serum creatinine by 9, e.g., if the serum creatinine concentration is 2 mg per 100 mL, the recommended single dose (7.5 mg/kg) should be administered every 18 hours.
Reduced Dosage at Fixed Time Intervals When renal function is impaired and it is desirable to administer amikacin at a fixed time interval, dosage must be reduced. In these patients, serum amikacin concentrations should be measured to assure accurate administration of amikacin and to avoid concentrations above 35 mcg/mL.
If serum assay determinations are not available and the patient's condition is stable, serum creatinine and creatinine clearance values are the most readily available indicators of the degree of renal impairment to use as a guide for dosage. First, initiate therapy by administering a normal dose, 7.5 mg/kg, as a loading dose.
This loading dose is the same as the normally recommended dose which would be calculated for a patient with a normal renal function as described above. To determine the size of maintenance doses administered every 12 hours, the loading dose should be reduced in proportion to the reduction in the patient's creatinine clearance rate: An alternate rough guide for determining reduced dosage at 12-hour intervals (for patients whose steady state serum creatinine values are known) is to divide the normally recommended dose by the patient's serum creatinine.
The above dosage schedules are not intended to be rigid recommendations but are provided as guides to dosage when the measurement of amikacin serum levels is not feasible. Creatinine Clearance Rate Intravenous Administration The individual dose, the total daily dose, and the total cumulative dose of amikacin sulfate are identical to the dose recommended for intramuscular administration.
The solution for intravenous use is prepared by adding the contents of a 500 mg vial to 100 or 200 mL of sterile diluent such as 0.9% sodium chloride injection or 5% dextrose injection or any of the compatible solutions listed below. The solution is administered to adults over a 30 to 60 minute period. The total daily dose should not exceed 15 mg/kg/day and may be divided into either 2 or 3 equally-divided doses at equally-divided intervals.
In pediatric patients the amount of fluid used will depend on the amount of amikacin ordered for the patient. It should be a sufficient amount to infuse the Amikacin Sulfate Injection, USP over a 30 to 60 minute period. Infants should receive a 1 to 2 hour infusion. Amikacin should not be physically premixed with other drugs but should be administered separately according to the recommended dose and route.
Stability in IV Fluids Amikacin sulfate is stable for 24 hours at room temperature at concentrations of 0.25 and 5 mg per mL in the following solutions: 5% Dextrose Injection, USP 5% Dextrose and 0.2% Sodium Chloride Injection, USP 5% Dextrose and 0.45% Sodium Chloride Injection, USP 0.9% Sodium Chloride Injection, USP Lactated Ringer's Injection, USP Normosol ® M in 5% Dextrose Injection (or Plasma-Lyte 56 Injection in 5% Dextrose in Water) Normosol ® R in 5% Dextrose Injection (or Plasma-Lyte 148 Injection in 5% Dextrose in Water) In the above solutions with Amikacin Sulfate Injection concentrations of 0.25 and 5 mg per mL, solutions aged for 60 days at 4°C and then stored at 25°C had utility times of 24 hours. At the same concentrations, solutions frozen and aged for 30 days at -15°C, thawed, and stored at 25°C had utility times of 24 hours.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit. Aminoglycosides administered by any of the above routes should not be physically premixed with other drugs but should be administered separately. Because of the potential toxicity of aminoglycosides, “fixed dosage” recommendations which are not based upon body weight are not advised.
Rather, it is essential to calculate the dosage to fit the needs of each patient.
Dosing: Altered kidney function
Amikacin is an aminoglycoside excreted almost entirely unchanged by the kidneys; it is nephrotoxic and ototoxic (boxed warning), with higher risk in kidney impairment, high doses and long courses. The US label adjusts by serum creatinine or creatinine clearance, either by lengthening the interval (serum creatinine × 9 hours) or by reducing the dose, with serum-level monitoring. It does not give a dialysis dose. Hemodialysis and peritoneal dialysis remove it.
Kidney function measure: Label uses serum creatinine (interval = SCr × 9 h) or creatinine clearance (proportional reduction); no fixed bands.
Show full dosing details
- CrCl ≥60 mL/min
- Normal kidney function: 15 mg/kg/day in 2 or 3 equal doses (7.5 mg/kg every 12 hours or 5 mg/kg every 8 hours); maximum 1.5 g/day; 7 to 10 days usual (label). If serum creatinine is raised, adjust as below. Monitor levels.
- CrCl 30–59 mL/min
- Give the normal 7.5 mg/kg loading dose, then either extend the interval (hours = serum creatinine in mg/dL × 9) or, at fixed 12-hour intervals, reduce the dose in proportion to CrCl (or divide the normal dose by serum creatinine) (label). Measure peaks and troughs: avoid peak above 35 mcg/mL and trough above 10 mcg/mL.
- CrCl 15–29 mL/min
- Give the normal 7.5 mg/kg loading dose, then either extend the interval (hours = serum creatinine in mg/dL × 9) or, at fixed 12-hour intervals, reduce the dose in proportion to CrCl (or divide the normal dose by serum creatinine) (label). Measure peaks and troughs: avoid peak above 35 mcg/mL and trough above 10 mcg/mL.
- CrCl <15 mL/min (not on dialysis)
- Give the normal 7.5 mg/kg loading dose, then either extend the interval (hours = serum creatinine in mg/dL × 9) or, at fixed 12-hour intervals, reduce the dose in proportion to CrCl (or divide the normal dose by serum creatinine) (label). Measure peaks and troughs: avoid peak above 35 mcg/mL and trough above 10 mcg/mL. Toxicity risk is highest here; specialist input.
- Hemodialysis (intermittent)
- The label's kidney methods should not be used during dialysis and no dialysis dose is given; hemodialysis removes amikacin (label). Dose by serum levels after dialysis with specialist input.
- Peritoneal dialysis
- No PD dose in label; peritoneal dialysis removes amikacin. For PD-associated peritonitis (ISPD 2022): 2 mg/kg intraperitoneally once daily, intermittent (in one exchange daily with a dwell of at least 6 hours); continuous dosing is not advised. Specialist input.
- CRRT
- Li 2020 (CRRT review): first dose of at least 25 mg/kg for target peaks in CVVHDF; 25 mg/kg every 48 hours with therapeutic drug monitoring in CVVH or CVVHDF (30 mL/kg/h). CVVHD: no accurate regimen; individualize from first-dose levels.
- Dialyzable? Yes: hemodialysis and peritoneal dialysis remove amikacin (label 10). Protein binding 0% to 11%.
- Monitoring Peak (30 to 90 minutes after dose) and trough levels; serum creatinine or CrCl before and during therapy; urinalysis; audiometry and vestibular function, especially with kidney impairment or courses over 10 days. Avoid other nephrotoxic or ototoxic drugs and potent diuretics.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual 15 mg/kg/day in 2 or 3 doses; TDM (label).
- eGFR 30–59
- Label kidney methods (interval = serum creatinine × 9 h, or proportional dose reduction) are not age-limited; monitor levels.
- eGFR 15–29
- As above; monitor levels.
- eGFR <15 (not on dialysis)
- As above; specialist input.
- Hemodialysis (intermittent)
- No label dose; level-guided; specialist.
- Peritoneal dialysis
- No label dose; see ISPD 2022; specialist.
- CRRT
- No pediatric CRRT data in the cited sources; level-guided; specialist.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
Patients with Impaired Renal Function Whenever possible, serum amikacin concentrations should be monitored by appropriate assay procedures. Doses may be adjusted in patients with impaired renal function either by administering normal doses at prolonged intervals or by administrating reduced doses at a fixed interval. Both methods are based on the patient's creatinine clearance or serum creatinine values since these have been found to correlate with aminoglycoside half-lives in patients with diminished renal function.
These dosage schedules must be used in conjunction with careful clinical and laboratory observations of the patient and should be modified as necessary. Neither method should be used when dialysis is being performed. Normal Dosage at Prolonged Intervals If the creatinine clearance rate is not available and the patient's condition is stable, a dosage interval in hours for the normal dose can be calculated by multiplying the patient's serum creatinine by 9, e.g., if the serum creatinine concentration is 2 mg per 100 mL, the recommended single dose (7.5 mg/kg) should be administered every 18 hours.
Reduced Dosage at Fixed Time Intervals When renal function is impaired and it is desirable to administer amikacin at a fixed time interval, dosage must be reduced. In these patients, serum amikacin concentrations should be measured to assure accurate administration of amikacin and to avoid concentrations above 35 mcg/mL.
If serum assay determinations are not available and the patient's condition is stable, serum creatinine and creatinine clearance values are the most readily available indicators of the degree of renal impairment to use as a guide for dosage. First, initiate therapy by administering a normal dose, 7.5 mg/kg, as a loading dose.
This loading dose is the same as the normally recommended dose which would be calculated for a patient with a normal renal function as described above. To determine the size of maintenance doses administered every 12 hours, the loading dose should be reduced in proportion to the reduction in the patient's creatinine clearance rate: An alternate rough guide for determining reduced dosage at 12-hour intervals (for patients whose steady state serum creatinine values are known) is to divide the normally recommended dose by the patient's serum creatinine.
The above dosage schedules are not intended to be rigid recommendations but are provided as guides to dosage when the measurement of amikacin serum levels is not feasible. Creatinine Clearance Rate Intravenous Administration The individual dose, the total daily dose, and the total cumulative dose of amikacin sulfate are identical to the dose recommended for intramuscular administration.
The solution for intravenous use is prepared by adding the contents of a 500 mg vial to 100 or 200 mL of sterile diluent such as 0.9% sodium chloride injection or 5% dextrose injection or any of the compatible solutions listed below. The solution is administered to adults over a 30 to 60 minute period. The total daily dose should not exceed 15 mg/kg/day and may be divided into either 2 or 3 equally-divided doses at equally-divided intervals.
In pediatric patients the amount of fluid used will depend on the amount of amikacin ordered for the patient. It should be a sufficient amount to infuse the Amikacin Sulfate Injection, USP over a 30 to 60 minute period. Infants should receive a 1 to 2 hour infusion. Amikacin should not be physically premixed with other drugs but should be administered separately according to the recommended dose and route.
Stability in IV Fluids Amikacin sulfate is stable for 24 hours at room temperature at concentrations of 0.25 and 5 mg per mL in the following solutions: 5% Dextrose Injection, USP 5% Dextrose and 0.2% Sodium Chloride Injection, USP 5% Dextrose and 0.45% Sodium Chloride Injection, USP 0.9% Sodium Chloride Injection, USP Lactated Ringer's Injection, USP Normosol ® M in 5% Dextrose Injection (or Plasma-Lyte 56 Injection in 5% Dextrose in Water) Normosol ®
Dosing: Pediatric
- Approved ages
- Children and older infants; newborns with caution (label).
- Usual dose
- Children and older infants with normal kidney function: 15 mg/kg/day in 2 or 3 doses. Newborns: 10 mg/kg loading dose, then 7.5 mg/kg every 12 hours (label).
- Maximum dose
- 15 mg/kg/day.
- Neonates
- 10 mg/kg loading dose, then 7.5 mg/kg every 12 hours; half-life longer in premature and neonatal infants (renal immaturity; label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
Pediatric Use Aminoglycosides should be used with caution in premature and neonatal infants because of the renal immaturity of these patients and the resulting prolongation of serum half-life of these drugs.
Dosage forms
Philippines
- ) solution for injection: 50 mg/mL (100 mg/2 mL, 125 mg/mL (250 mg/2 mL, 125 mg/mL (250 mg/2 mL and 500 mg/4 mL, 250 mg mL (500 mg/2 mL, 250 mg/mL (500 mg/2 mL, 500 mg/2 mL (250 mg/mL
- Solution for injection: 50 mg/mL, 100 mg/mL, 125 mg/mL, 250 mg/2 mL, 250 mg/mL
Registered products in the Philippines
51 products registered with the Food and Drug Administration (FDA) Philippines list Amikacin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products51
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AbazineAmikacin (as sulfate) | 125mg/mL Solution for Injection (IM/IV)Type I Clear Glass Ampoule x 2mL and 4mL in PVC Tray (Box of 10's) | Rx | Friends Pharma (Pvt.) LtdPakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-17251 | Oct 24, 2031 | |
AecinAmikacin (as sulfate) | 250 mg/mL (500 mg/2mL) Solution for Injection (IM/IV)USP Type 1 clear tubular glass vial with 13 mm grey bromo butyl rubber stopper and sealed with 13 mm colored flip off seal x 2 mL (Box of 1’s) | Rx | Swiss Parenterals Ltd. (Block-B)India | Dynasty PharmaceuticalsImporter: 2MG Incorporated | DRP-13784-01 | Apr 19, 2028 | |
Ambikacin-100Amikacin (as sulfate) | 50 mg/mL (100 mg/2 mL) Solution for Injection (IM/IV)USP Type I Clear glass vial with grey bromobutyl rubber stopper and aluminum flip-off seal x 2 mL (Box of 1's) | Rx | Cooper Pharma LimitedIndia | Ambica International Corporation | DRP-13296 | Feb 8, 2028 | |
Ambikacin-250Amikacin (as sulfate) | 125 mg/mL (250 mg/2 mL) Solution for Injection (IM/IV)USP Type I Clear glass vial with grey bromobutyl rubber stopper and aluminum flip-off seal x 2 mL (Box of 1's) | Rx | Cooper Pharma LimitedIndia | Ambica International Corporation | DRP-13295 | Feb 8, 2028 | |
Ambikacin-500Amikacin (as sulfate) | 250 mg/mL (500 mg/2 mL) Solution for Injection (I.M./I.V.)2 mL USP Type I clear and colorless glass vial. enclosed with grey bromobutyl rubber closure and aluminum seal with purple plastic flip-off cap (Box of 1's) | Rx | Cooper Pharma LimitedIndia | Ambica International Corporation.Importer: Ambica International Corporation | DRP-13701 | Mar 29, 2028 | |
AmicareAmikacin (as Sulfate) | 125 mg/mL (250 mg/2 mL) Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 2 mL (Box of 10's) | Rx | SUICHENG PHARMACEUTICAL CO., LTD.China | AGLOBAL CARE, INC. | DRP-6137 | May 26, 2029 | |
AmicynAmikacin (as Sulfate) | 100 mg/mL Solution for Injection (IM/IV)2 mL Clear Vial (Box of 10's) | Rx | Yung Shin Pharmaceutical Ind., Co., Ltd. (Taichung Youth Factory)Taiwan | Dynasty PharmaceuticalsImporter: Yung Shin (Philippines), Inc. | DRP-1040-01 | Jul 29, 2027 | |
AmicynAmikacin (as Sulfate) | 250 mg/mL (500 mg/2mL) Solution for Injection (IM/IV)Clear Glass Vial x 2 mL with Rubber Stopper and Yellow Flip-off seal (Box of 10's) | Rx | Yung Shin Pharmaceutical Ind. Co., Ltd. (Taichung Youth Factory)Taiwan | Dynasty PharmaceuticalsImporter: Yung Shin (Philippines), Inc. | DRP-1041-01 | Sep 13, 2027 | |
AmigetAmikacin (as sulfate) | 250 mg/mL (500 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type 1 clear tubular glass vial with 13 mm grey bromo butyl rubber stopper and sealed with 13 mm colored flip off seal x 2 mL (Box of 1's) | Rx | Swiss Parenterals Ltd. (Block-B)India | 2MG Incorporated | DRP-13784 | Apr 19, 2028 | |
Amikacent-100Amikacin (as sulfate) | 50 mg/mL Solution for Injection (I.M./I.V.)2 mL Type I clear and colorless glass vial enclosed with gray bromobutyl rubber stopper and aluminum seal with white plastic flip-off cap (Box of 1's) | Rx | Hiral Labs LimitedIndia | Central West Medicale Inc.Importer: Bellus Life Solutions, Inc | DRP-13497-02 | Feb 28, 2028 | |
Amikacent-250Amikacin (as sulfate) | 125 mg/mL Solution for Injection (I.M./I.V.)2 mL Type I clear and colorless glass vial enclosed with gray bromobutyl rubber stopper and aluminum seal with white plastic flip-off cap (Box of 1's) | Rx | Hiral Labs LimitedIndia | Central West Medicale Inc.Importer: Bellus Life Solutions, Inc. | DRP-13498-02 | Feb 28, 2028 | |
Amikacent-500Amikacin (as sulfate) | 250 mg/mL Solution for injection (I.M./I.V.)2 mL Type I clear and colorless glass vial enclosed with gray bromobutyl rubber stopper and aluminum seal with blue plastic flip-off cap (Box of 1's) | Rx | Hiral Labs LimitedIndia | Central West Medicale Inc.Importer: Bellus Life Solutions, Inc. | DRP-13499-02 | Feb 28, 2028 | |
AmikacideAmikacin (as Sulfate) | 125 mg/mL Solution for Injection (IM/IV)3 mL Clear Glass Ampoule (2 mL net content) [Box of 5's] | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY17729 | Jul 8, 2027 | |
AmikacideAmikacin (as sulfate) | 250 mg/mL Solution for Injection (I.M./I.V.)Type I Clear Glass Ampoule with Blue Dot x 3 mL (Box of 5's) | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY17731 | May 13, 2027 | |
AmikacideAmikacin (as sulfate) | 50 mg/mL Solution for Injection (I.M./I.V.)Type I Clear Glass Ampoule with Blue Dot x 3 mL (Box of 5's) | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DR‐XY17730 | May 13, 2027 | |
Amikacy-125Amikacin (as sulfate) | 125 mg/mL Solution for Injection (I.M./I.V.)2 mL Type I clear and colorless glass vial enclosed with gray bromobutyl rubber stopper and aluminum seal with white plastic flip-off cap (Box of 1's) | Rx | Hiral Labs LimitedIndia | Bellus Life Solutions, Inc. | DRP-13498 | Feb 28, 2028 | |
Amikacy-250Amikacin (as sulfate) | 250 mg/mL Solution for Injection (I.M./I.V.)2 mL Type I clear and colorless glass vial enclosed with gray bromobutyl rubber stopper and aluminum seal with blue plastic flip-off cap (Box of 1's) | Rx | Hiral Labs LimitedIndia | Bellus Life Solutions, Inc. | DRP-13499 | Feb 28, 2028 | |
Amikacy-50Amikacin (as sulfate) | 50 mg/mL Solution for Injection (I.M./I.V.)2 mL Type I clear and colorless glass vial enclosed with gray bromobutyl rubber stopper and aluminum seal with green plastic flip-off cap (Box of 1's) | Rx | Hiral Labs LimitedIndia | Bellus Life Solutions, Inc. | DRP-13497 | Feb 28, 2028 | |
Amikamed-500Amikacin (as sulfate) | 250 mg/mL (500 mg/2 mL) Solution for Injection (IM/IV)2 mL USP Type I clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with blue plastic flip-off cap (Box of 1's) | Rx | Shree Anand Life Sciences Ltd.India | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaeutical, Inc. | DRP-16510-01 | Apr 3, 2030 | |
AmikateAmikacin (as sulfate) | 125 mg/mL (250 mg/2 mL) Solution for Injection (I.M./I.V.)Clear colourless tubular glass vial with bromo butyl rubber stopper and aluminum flip-off seal and white polypropylene cap x 2 mL (Box of 5's) | Rx | Skymap Healthcare Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-14403 | Sep 5, 2028 | |
AmikenAmikacin (as sulfate) | 250 mg/mL (500 mg/2 mL) Solution for Injection (I.M./I.V.)Type 1 clear glass vial plugged with 13 mm bromo butyl rubber stopper, and sealed with 13 mm red flip off seal x 2 mL ( Box of 1's) | Rx | Skymap Healthacre Pvt. Ltd.India | AMB HK Enterprises, Inc. | DRP-17122 | Oct 3, 2030 | |
Amikhriz 500Amikacin (as sulfate) | 250 mg mL (500 mg/2 mL) Solution For Injection2 mL USP Type I Clear vial with gray butyl rubber plug (Box of 1's % 10's) | Rx | Merit Organics Ltd.India | Khriz Pharma Trading Inc. | DRP-19005 | Oct 15, 2031 | |
AminicaAmikacin (as sulfate) | 125 mg/mL (250 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type 1 clear glass ampoule x 2 mL (Box of 10's) | Rx | Anhui Chengshi Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-14402 | Sep 5, 2028 | |
Amisac-500Amikacin | 500 mg/2 mL (250 mg/mL) Solution for Injection (IM/IV)USP Type I Glass Vial enclosed with butyl rubber stopper and aluminum seal with blue flip-off cap x 2 mL Box of 1’s | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-8835 | Apr 29, 2030 | |
Amisave-100Amikacin (as sulfate) | 50 mg / mL Solution for Injection (I.M./I.V.)2 mL Type I clear colorless glass vial enclosed with gray bromobutyl rubber stopper and aluminum seal with green plastic flip-off cap (Box of 1's) | Rx | Hiral Labs LimitedIndia | Savelink Pharma and Trading Co.Importer: Bellus Life Solutions, Inc | DRP-13497-03 | Feb 28, 2028 | |
Amisave-250Amikacin (as sulfate) | 125 mg/mL Solution for Injection (I.M./I.V.)2 mL Type I clear and colorless glass vial enclosed with gray bromobutyl rubber stopper and aluminum seal with white plastic flip-off cap (Box of 1's) | Rx | Hiral Labs LimitedIndia | Savelink Pharma And Trading Co.Importer: Bellus Life Solutions, Inc | DRP-13498-03 | Feb 28, 2028 | |
Amisave-500Amikacin (as sulfate) | 250 mg/mL Solution for Injection (I.M./I.V.)2 mL Type I clear and colorless glass vial enclosed with gray bromobutyl rubber stopper and aluminum seal with blue plastic flip-off cap (Box of 1's) | Rx | Hiral Labs LimitedIndia | Savelink Pharma And Trading Co.Importer: Bellus Life Solutions, Inc | DRP-13499-03 | Feb 28, 2028 | |
AmkalonAmikacin (as sulfate) | 250 mg/2 mL Solution for Injection (I.M./I.V.)USP Type II Clear Glass Vial with Aluminum Flip-off Seal with Light Pink Color Plastic Material x 2 mL (Box of 1's) | Rx | Norris Medicines LimitedIndia | Vivilon Pharmaceuticals Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Private Limited | DRP-4552-01 | Jul 26, 2028 | |
AmkalonAmikacin (as sulfate) | 50 mg/mL Solution for Injection (I.M./I.V.)USP Type I Clear Glass Vial x 2 mL (Box of 1's) | Rx | Norris Medicines LimitedIndia | Vivilon Pharmaceuticals Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Private Limited | DRP-4485-01 | Jun 17, 2028 | |
AmkarightAmikacin (as sulfate) | 250 mg/2 mL Solution for Injection (I.M./I.V.)USP Type II Clear Glass Vial with Aluminum Flip-off Seal with Light Pink Color Plastic Material x 2 mL (Box of 1's) | Rx | Norris Medicines LimitedIndia | Meedpharma Medical Supplies & Equipment DistributorImporter: Medethix, Inc.Trader: Alvita Pharma Private Limited | DRP-4552 | Jul 26, 2028 | |
AmkarightAmikacin (as sulfate) | 50 mg/mL Solution for Injection (I.M./I.V.)USP Type I Clear Glass Vial x 2 mL (Box of 1's) | Rx | Norris Medicines LimitedIndia | Medethix, Inc,Trader: Alvita Pharma Private Limited | DRP-4485 | Jun 17, 2028 | |
CinmikAmikacin (as Sulfate) | 125mg/mL Solution for Injection (I.M./I.V.)Clear Glass Vial x 2 mL (Box of 10's) | Rx | Karnataka Antibiotics & Pharmaceuticals Ltd.India | Phil. Pharmawealth, Inc. | DR-XY29049 | Oct 13, 2030 | |
CinmikAmikacin (as Sulfate) | 250mg/mL (500mg/2mL) Solution for Injection (I.M./I.V.)Clear Glass Vial x 2mL (Box of 10's) | Rx | Karnataka Antibiotics & Pharmaceuticals Ltd.India | Phil. Pharmawealth, Inc. | DR-XY29193 | Nov 27, 2030 | |
CinmikAmikacin (as Sulfate) | 50mg/mL (100mg/2mL) Solution for Injection (I.M./I.V.)Clear Glass Vial x 2mL (Box of 10's) | Rx | Karnataka Antibiotics & Pharmaceuticals Ltd.India | Phil. Pharmawealth, Inc. | DR-XY29194 | Nov 27, 2030 | |
CocineAmikacin (as sulfate) | 125 mg/mL (250 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I clear glass vial with gray butyl rubber stopper and flip off seal x 2 mL (net content). (Box of 10's) | Rx | Scott-Edil Pharmacia LimitedIndia | Greencore Pharma Inc. | DRP-9625 | Apr 13, 2031 | |
CocineAmikacin (as sulfate) | 250 mg/mL (500 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I clear glass vial with gray butyl rubber stopper and flip off seal x 2 mL (net content) (Box of 10's) | Rx | Scott-Edil Pharmacia LimitedIndia | Greencore Pharma Inc. | DRP-9624 | Apr 13, 2031 | |
CocineAmikacin (as sulfate) | 50 mg/mL (100 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I clear glass vial with gray butyl rubber stopper and flip off seal x 2 mL (net content) (Box of 10's) | Rx | Scott-Edil Pharmacia LimitedIndia | Greencore Pharma Inc.Importer: Greencore Pharma Inc.Greencore Pharma Inc. | DRP-9626 | Apr 13, 2031 | |
EkacinAmikacin (as sulfate) | 250 mg/mL (500 mg/2 mL) Solution for Injection (IM/IV)USP Type I amber colour glass ampoule x 2 mL (net content) (Box of 5's and 10's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-9576 | Mar 3, 2031 | |
Gokacin-100Amikacin (as sulfate) | 50 mg/mL Solution for Injection (I.M./I.V.)2 mL Type I clear and colorless glass vial enclosed with gray bromobutyl rubber stopper and aluminum seal with green plastic flip - off cap (Box of 1's) | Rx | Hiral Labs LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Bellus Life Solutions, Inc. | DRP-13497-01 | Feb 28, 2028 | |
Gokacin-250Amikacin (as sulfate) | 125 mg/mL Solution for Injection (I.M./I.V.)2 mL Type I Clear and Colorless Glass Vial enclosed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with white Plastic Flip-Off Cap (Box of 1's) | Rx | Hiral Labs LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Bellus Life Solutions, Inc. | DRP-13498-01 | Feb 28, 2028 | |
Gokacin-500Amikacin (as sulfate) | 250 mg/mL Solution for Injection (I.M./I.V.)2 mL Type I clear and colorless glass vial enclosed with gray bromobutyl rubber stopper and aluminum seal with blue plastic flip-off cap (Box of 1's) | Rx | Hiral Labs LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Bellus Life Solutions, Inc. | DRP-13499-01 | Feb 28, 2028 | |
KasitrexAmikacin (As sulfate) | 250 mg/mL (500 mg/2mL) Solution For Injection (I.M/I/V.)USP Type I glass vial x 2 mL (net content) with gray butyl rubber stopper, aluminum seal and flip-off cap (Box of 1’s and 10’s) | Rx | Kwality Pharmaceuticals Ltd.India | Janamed Corporation | DRp-18172 | May 26, 2031 | |
LadkinAmikacin (as sulfate) | 250 mg/mL (500 mg/2mL) Solution for Injection (IM/IV)Clear colorless Type I glass vial x 2mL with rubber stopper and white flip-off seal Box of 1's | Rx | T.P. Drug Laboratories (1969) Co., Ltd.Thailand | Lordla Pharma Sales | DR-XY23449 | Oct 29, 2027 | |
MakcinAmikacin (as sulfate) | 250 mg/mL (500 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I clear glass vial with grey butyl rubber stopper and flip of seal x 2 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Hillcross Prime, Inc. | DRP-9807 | Jun 9, 2036 | |
MikacilifeAmikacin (as sulfate) | 125 mg/mL Solution For Injection (I.M./I.V.)USP Type I clear glass ampoule x 2 mL & 4 mL (net content) in a PVC plastic tray (Box of 10’s) | Rx | Anhil Parenteral Pvt. Ltd.India | Biophil Medical Equipment and Supplies Trading | DRP-18551 | Jul 29, 2031 | |
MikacilifeAmikacin (as Sulfate) | 250 mg/mL Solution For Injection (I.M./I.V.)USP Type I clear glass ampoule x 2 mL & 4 mL (net content) in a PVC plastic tray (Box of 10's) | Rx | Anhil Parenteral Pvt. Ltd.India | Biophil Medical Equipment and Supplies Trading | DRP-18550 | Jul 29, 2031 | |
MikaporsAmikacin (As Sulfate) | 125 mg/mL (250 mg/2 mL and 500 mg/4 mL) Solution for Injection (IM/IV)Clear USP Type I Glass Ampoule x 2 mL and 4 mL with Plastic Tray (Box of 10's) | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DRP-17915 | Apr 7, 2031 | |
NicaAmikacin Sulfate | 100 mg/mL Solution for Injection (IM/IV)2 mL Clear Vial (Box of 10's) | Rx | Yung Shin Pharm. Ind. Co., Ltd. (Taichung Youth Factory)Taiwan | Yung Shin (Philippines), Inc. | DRP-1040 | Jul 29, 2027 | |
NicaAmikacin (as Sulfate) | 250 mg/mL (500 mg/2 mL) Solution for Injection (IM/IV)Clear Glass Vial x 2 mL with Rubber Stopper and Yellow Flip-off Seal Box of 10's | Rx | Yung Shin Pharmaceutical Ind. Co., Ltd. (Taichung Youth Factory)Taiwan | Yung Shin (Philippines), Inc. | DRP-1041 | Sep 13, 2027 | |
NoneAmikacin (as sulfate) | 250 mg/mL (500mg/2mL) Solution for Injection (IM/IV)Clear Glass Vial x 2 mL Box of 1's | Rx | Concept Pharmaceuticals Ltd.India | Medethix, Inc. | DRP-13571 | Mar 10, 2030 | |
Quikacin-500Amikacin (as sulfate) | 250 mg/mL (500 mg/2 mL) Solution for Injection (IM/IV)2 mL USP Type I clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with blue plastic stic flip-off cap (Box of 1's) | Rx | Shree Anand Life Sciences Ltd.India | Medinova Pharmaceutical, Inc. | DRP-16510 | Apr 3, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
The boxed warning is shown at the top of this page.
Warnings and precautions (US label) US FDA label
WARNINGS See WARNINGS box above. Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycosides cross the placenta and there have been several reports of total irreversible, bilateral congenital deafness in children whose mothers received streptomycin during pregnancy. Although serious side effects to the fetus or newborns have not been reported in the treatment of pregnant women with other aminoglycosides, the potential for harm exists.
Reproduction studies of amikacin have been performed in rats and mice and revealed no evidence of impaired fertility or harm to the fetus due to amikacin. There are no well controlled studies in pregnant women, but investigational experience does not include any positive evidence of adverse effects to the fetus. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than nonasthmatic people.
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Amikacin Sulfate Injection, USP, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use.
Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Risk of Ototoxicity Due to Mitochondrial DNA Variants Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m. 1555A>G variant. Ototoxicity occurred in some patients even when their aminoglycoside serum levels were within the recommended range.
Mitochondrial DNA variants are present in less than 1% of the general US population, and the proportion of the variant carriers who may develop ototoxicity as well as the severity of ototoxicity is unknown. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Other nephrotoxic or neurotoxic drugs (vancomycin, amphotericin B, colistin, polymyxin B, cisplatin, other aminoglycosides) | Avoid | Additive nephrotoxicity and ototoxicity (label). | Avoid; if needed, monitor levels and kidney function. |
| Potent diuretics (furosemide, ethacrynic acid) | Avoid | Ototoxicity; altered aminoglycoside levels (label). | Avoid the combination. |
| Neuromuscular blockers, anesthesia | Adjust or monitor | Neuromuscular blockade, respiratory paralysis (label). | Monitor; calcium may reverse. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedMetabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
The peak fetal serum concentration is about 16% of the peak maternal serum concentration and maternal and fetal serum half-life values are about 2 and 3.7 hours, respectively.
Adverse reactions
Common
- Nephrotoxicity (casts, protein, rising creatinine)
- Ototoxicity: tinnitus, hearing loss, vertigo
Serious
- Acute kidney injury (boxed warning)
- Irreversible hearing loss and vestibular toxicity (boxed warning)
- Neuromuscular blockade and respiratory paralysis
- Hypersensitivity
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS All aminoglycosides have the potential to induce auditory, vestibular, and renal toxicity and neuromuscular blockade (see WARNINGS box). They occur more frequently in patients with present or past history of renal impairment, of treatment with other ototoxic or nephrotoxic drugs, and in patients treated for longer periods and/or with higher doses than recommended.
Neurotoxicity-Ototoxicity Toxic effects on the eighth cranial nerve can result in hearing loss, loss of balance, or both. Amikacin primarily affects auditory function. Cochlear damage includes high frequency deafness and usually occurs before clinical hearing loss can be detected. Neurotoxicity-Neuromuscular Blockade Acute muscular paralysis and apnea can occur following treatment with aminoglycoside drugs.
Nephrotoxicity Elevation of serum creatinine, albuminuria, presence of red and white cells, casts, azotemia, and oliguria have been reported. Renal function changes are usually reversible when the drug is discontinued. As would be expected with any aminoglycoside, reports of toxic nephropathy and acute renal failure have been received during postmarketing surveillance.
Other In addition to those described above, other adverse reactions which have been reported on rare occasions are skin rash, drug fever, headache, paresthesia, tremor, nausea and vomiting, eosinophilia, arthralgia, anemia, hypotension anemia, hypotension and hypomagnesemia. Macular infarction sometimes leading to permanent loss of vision has been reported following intravitreous administration (injection into the eye) of amikacin.
To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Monitoring parameters
- Peak (30 to 90 minutes after dose) and trough levels; serum creatinine or CrCl before and during therapy; urinalysis; audiometry and vestibular function, especially with kidney impairment or courses over 10 days. Avoid other nephrotoxic or ototoxic drugs and potent diuretics. Kidney
- Peak and trough levels
- Serum creatinine or CrCl
- Hearing and vestibular function
- Urinalysis
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic Effects (See WARNINGS section.)
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers It is not known whether amikacin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from amikacin, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Mechanism of action
Mechanism of Action Amikacin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria. It is bactericidal in vitro against Gram-positive and Gram-negative bacteria.
US FDA labelPharmacokinetics
Key PK parameters
| Bioavailability | Not absorbed orally (IM complete) |
|---|---|
| Half-life | Slightly over 2 hours |
| Half-life in kidney failure (ESKD) kidney | Markedly prolonged (label) |
| Volume of distribution | About 24 L (28% of body weight) |
| Protein binding | 0% to 11% |
| Metabolism (CYP, transporters) | Not metabolized |
| Active metabolites | None |
| Renal excretion kidney | About 98% unchanged in urine within 24 hours |
| Dialyzability kidney | Yes, by hemodialysis and peritoneal dialysis (label) |
With normal renal function, about 91.9% of an intramuscular dose is excreted unchanged in the urine in the first 8 hours, and 98.2% within 24 hours.
Preliminary intramuscular studies in newborns of different weights (less than 1.5 kg, 1.5 to 2.0 kg, over 2.0 kg) at a dose of 7.5 mg/kg revealed that, like other aminoglycosides, serum half-life values were correlated inversely with post-natal age and renal clearances of amikacin.
Eighty-four percent of the administered dose was excreted in the urine in 9 hours and about 94% within 24 hours.
General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
The mean serum clearance rate is about 100 mL/min and the renal clearance rate is 94 mL/min in subjects with normal renal function.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Intramuscular Administration Amikacin is rapidly absorbed after intramuscular administration. In normal adult volunteers, average peak serum concentrations of about 12, 16, and 21 mcg/mL are obtained 1 hour after intramuscular administration of 250 mg (3.7 mg/kg), 375 mg (5 mg/kg), 500 mg (7.5 mg/kg), single doses, respectively.
At 10 hours, serum levels are about 0.3 mcg/mL, 1.2 mcg/mL, and 2.1 mcg/mL, respectively. Tolerance studies in normal volunteers reveal that amikacin is well tolerated locally following repeated intramuscular dosing, and when given at maximally recommended doses, no ototoxicity or nephrotoxicity has been reported. There is no evidence of drug accumulation with repeated dosing for 10 days when administered according to recommended doses.
With normal renal function, about 91.9% of an intramuscular dose is excreted unchanged in the urine in the first 8 hours, and 98.2% within 24 hours. Mean urine concentrations for 6 hours are 563 mcg/mL following a 250 mg dose, 697 mcg/mL following a 375 mg dose, and 832 mcg/mL following a 500 mg dose. Preliminary intramuscular studies in newborns of different weights (less than 1.5 kg, 1.5 to 2.0 kg, over 2.0 kg) at a dose of 7.5 mg/kg revealed that, like other aminoglycosides, serum half-life values were correlated inversely with post-natal age and renal clearances of amikacin.
The volume of distribution indicates that amikacin, like other aminoglycosides, remains primarily in the extracellular fluid space of neonates. Repeated dosing every 12 hours in all the above groups did not demonstrate accumulation after 5 days. Intravenous Administration Single doses of 500 mg (7.5 mg/kg) administered to normal adults as an infusion over a period of 30 minutes produced a mean peak serum concentration of 38 mcg/mL at the end of the infusion, and levels of 24 mcg/mL, 18 mcg/mL, and 0.75 mcg/mL at 30 minutes, 1 hour, and 10 hours post-infusion, respectively.
Eighty-four percent of the administered dose was excreted in the urine in 9 hours and about 94% within 24 hours. Repeat infusions of 7.5 mg/kg every 12 hours in normal adults were well tolerated and caused no drug accumulation. General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
By the ultrafiltration technique, reports of serum protein binding range from 0 to 11%. The mean serum clearance rate is about 100 mL/min and the renal clearance rate is 94 mL/min in subjects with normal renal function. Amikacin is excreted primarily by glomerular filtration. Patients with impaired renal function or diminished glomerular filtration pressure excrete the drug much more slowly (effectively prolonging the serum half-life).
Therefore, renal function should be monitored carefully and dosage adjusted accordingly (see suggested dosage schedule under DOSAGE AND ADMINISTRATION). Following administration at the recommended dose, therapeutic levels are found in bone, heart, gallbladder, and lung tissue in addition to significant concentrations in urine, bile, sputum, bronchial secretions, interstitial, pleural, and synovial fluids.
Spinal fluid levels in normal infants are approximately 10 to 20% of the serum concentrations and may reach 50% when the meninges are inflamed. Amikacin has been demonstrated to cross the placental barrier and yield significant concentrations in amniotic fluid. The peak fetal serum concentration is about 16% of the peak maternal serum concentration and maternal and fetal serum half-life values are about 2 and 3.7 hours, respectively.
Microbiology Mechanism of Action Amikacin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria. It is bactericidal in vitro against Gram-positive and Gram-negative bacteria. Mechanism of Resistance Aminoglycosides are known to be ineffective against Salmonella and Shigella species in patients.
Therefore, in vitro susceptibility test results should not be reported. Amikacin resists degradation by certain aminoglycoside inactivating enzymes known to affect gentamicin, tobramycin, and kanamycin. Aminoglycosides in general have a low order of activity against Gram-positive organisms other than Staphylococcal isolates.
Interaction with Other Antimicrobials In vitro studies have shown that amikacin sulfate combined with a beta-lactam antibiotic acts synergistically against many clinically significant Gram-negative organisms. Antimicrobial Activity Amikacin has been shown to be active against the following bacteria, both in vitro and in clinical infections (see INDICATIONS AND USAGE).
Gram-positive Bacteria Staphylococcus species Gram-negative Bacteria Pseudomonas species Escherichia coli Proteus species (indole-positive and indole-negative) Klebsiella species Enterobacter species Serratia species Acinetobacter species Amikacin has demonstrated in vitro activity against the following bacteria. The safety and effectiveness of amikacin in treating clinical infections due to these bacteria have not been established in adequate and well-controlled trials.
Citrobacter freundii Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Amikacin (as Sulfate) 50 mg/mL, 2 mL Ampule | ₱18.32–₱64.34Reference ₱18.32 | per ampule | DPRI procurement range |
| Amikacin (as Sulfate) 50 mg/ml, 2 ml Vial | ₱18.32–₱36.45Reference ₱20.38 | per vial | DPRI procurement range |
| Amikacin (as Sulfate) 100 mg powder Vial | ₱15.50–₱18.29Reference ₱15.50 | per vial | DPRI procurement range |
| Amikacin (as Sulfate) 125 mg/mL, 2 mL Ampule | ₱17.10–₱74.80Reference ₱34.89 | per ampule | DPRI procurement range |
| Amikacin (as Sulfate) 125 mg/mL, 2 mL Vial | ₱15.33–₱42.23Reference ₱21.34 | per vial | DPRI procurement range |
| Amikacin (as Sulfate) 250 mg/mL, 2 mL Ampule | ₱23.22–₱400.00Reference ₱43.33 | per ampule | DPRI procurement range |
| Amikacin (as Sulfate) 250 mg/mL, 2 mL Vial | ₱19.11–₱93.44Reference ₱30.74 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Amikacin (as sulfate) |
| PNF listing | Inj.: 50 mg/mL, 100 mg/mL, 125 mg/mL and 250 mg/mL, |
| PNF listing | Inj.: 2 mL ampul/vial (IM, IV) |
| PNF listing | Inj.: 100 mg, 250 mg, 500 mg and 1 g vial (IM, IV) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. amikacin sulfate · Sagent Pharmaceuticals [US FDA-approved label, version 10, July 27, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f260ff2a-76a0-4672-9516-91c344b67890
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Sagent Pharmaceuticals. (2026). Amikacin sulfate injection [Prescribing information; US FDA-approved label, ANDA203323, set ID f260ff2a-76a0-4672-9516-91c344b67890, version effective July 27, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f260ff2a-76a0-4672-9516-91c344b67890
- Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
- Li, P. K., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y. L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .